Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HBB | P68871 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515941 | 1.00 | ALDH1A1 (0.33) | ALDH1A1HBBHSD17B10GRM2 | |
| SCHEMBL18751689 | 0.88 | POLB (0.34) | ALDH1A1HBBHSD17B10 | |
| SCHEMBL12355150 | 0.86 | ALDH1A1 (0.30) | ALDH1A1HBBHSD17B10 | |
| SCHEMBL10031821 | 0.86 | GRM2 (0.31) | ALDH1A1HBBHSD17B10GRM2 | |
| SCHEMBL13661861 | 0.84 | BTK (0.38) | ALDH1A1HSD17B10 | |
| SCHEMBL25530270 | 0.84 | EPHX1 (0.31) | — | |
| SCHEMBL16501734 | 0.82 | BTK (0.30) | — | |
| SCHEMBL18751739 | 0.82 | CHRNB2 (0.38) | — | |
| SCHEMBL16704552 | 0.81 | POLB (0.37) | ALDH1A1HBBHSD17B10 | |
| SCHEMBL18751737 | 0.81 | POLB (0.37) | ALDH1A1HBBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017556-B2 | Insulin receptor partial agonists | MERCK SHARP & DOHME CORP. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-12-14 | — | — | US | disclosed |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355743-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | ALDH1A1 4716/4885HBB 162/4885HSD17B10 2172/4885 |
| US-10017556-B2 | Insulin receptor partial agonists | INSR, GPR119, IRS1 | ALDH1A1 4716/4885HBB 162/4885HSD17B10 2172/4885 |
| US-20170107268-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | ALDH1A1 4716/4885HBB 162/4885HSD17B10 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.